I’ve become the newsroom’s resident expert on financial statements and stock performance, as nearly all of San Diego’s public companies are biotechs. My quarterly report, “Bio Stocks,” launched this year, summing up the stock performance of local companies and providing analysis of that quarter’s “winners and losers.”

This localized insight into public companies helps our readers keep track of who’s on top, who’s struggling, and who might be an unknown but worthy investment.

Here’s an example this report: